UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest
Balance at beginning of period at Dec. 31, 2019	$ 917.1	$ 906.8	$ 1.7	$ (543.8)	$ 199.7	$ 1,274.7	$ (25.5)	$ 10.3	$ 21.1
Balance (in shares) at Dec. 31, 2019			154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7	0.7			0.7
Stock options exercised (in shares)			30,182
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			40,516
Stock based compensation	3.0	3.0			3.0
Dividends declared to common stockholders	(7.4)	(6.2)				(6.2)		(1.2)
Acquired remaining 20% interest in Hain LifeScience GmbH	(1.3)	(1.3)				(1.3)			(20.6)
Consolidated net income	10.6	10.5				10.5		0.1
Other comprehensive income (loss)	2.0	2.2					2.2	(0.2)	(0.5)
Balance at end of period at Mar. 31, 2020	924.6	915.6	$ 1.7	$ (543.8)	203.3	1,277.7	(23.3)	9.0
Balance (in shares) at Mar. 31, 2020			154,226,496	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.3	1.3			1.3
Stock options exercised (in shares)			61,968
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			3,510
Stock based compensation	2.8	2.8			2.8
Shares purchased	(50.0)	(50.0)		$ (50.0)
Shares purchased (in shares)			(1,214,282)	1,214,282
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	24.2	24.1				24.1		0.1
Other comprehensive income (loss)	9.9	9.8					9.8	0.1
Balance at end of period at Jun. 30, 2020	906.6	897.4	$ 1.7	$ (593.8)	207.3	1,295.7	(13.5)	9.2
Balance (in shares) at Jun. 30, 2020			153,077,692	20,560,859
Balance at beginning of period at Dec. 31, 2020	974.3	961.2	$ 1.7	$ (667.0)	216.3	1,406.5	3.7	13.1	0.0
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.2	1.2			1.2
Stock options exercised (in shares)			65,312
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			21,821
Stock based compensation	3.4	3.4			3.4
Shares purchased	(32.8)	(32.8)		$ (32.8)
Shares purchased (in shares)			(530,729)	530,729
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	57.8	56.7				56.7		1.1
Other comprehensive income (loss)	(16.0)	(15.8)					(15.8)	(0.2)
Balance at end of period at Mar. 31, 2021	981.7	967.7	$ 1.7	$ (699.8)	220.8	1,457.1	(12.1)	14.0
Balance (in shares) at Mar. 31, 2021			151,543,485	22,589,258
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.0	1.0			1.0
Stock options exercised (in shares)			64,783
RSU vested	0.0	0.0			0.0
RSU vested (in shares)			1,780
Stock based compensation	3.6	3.6			3.6
Shares purchased	(38.3)	(38.3)		$ (38.3)
Shares purchased (in shares)			(555,576)	555,576
Dividends declared to common stockholders	(6.0)	(6.0)				(6.0)
Formation of Acuity Spatial Genomics Inc.									0.3
Consolidated net income	58.7	57.6				57.6		1.1
Other comprehensive income (loss)	14.7	16.4					16.4	(1.7)
Balance at end of period at Jun. 30, 2021	$ 1,015.4	$ 1,002.0	$ 1.7	$ (738.1)	$ 225.4	$ 1,508.7	$ 4.3	$ 13.4	$ 0.3
Balance (in shares) at Jun. 30, 2021			151,054,472	23,144,834